$ARS Pharmaceuticals (SPRY.US)$ 10% Shareholder Flynn James E sold 563.27K shares of common stock on Nov 11, 12, 2024 at an average price of $18.01 for a total value of $10.14 million.
This transaction involves other related parties: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Private Design Fund IV, L.P..
What is statement of changes in beneficial ownership of securities?
It is a requirement under federal securities laws that mandates individuals, including officers, directors, and those who hold more than 10% of any class of a company's securities (collectively known as "insiders"), to report their purchases, sales, and holdings of their company's securities by submitting Forms 3, 4, and 5.
